The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose of the gene therapy against type 2 diabetes (T2D) and obesity that Fractyl Health Inc. is developing. Scientists from the Lexington, Mass.-based company have designed a strategy based on glucagon-like peptide-1 (GLP-1) to transform pancreatic cells and reverse the disease.

Absci Corp. and the University of Oxford’s...

Salipro Biotech AB and Dynabind GmbH have achieved a key milestone under their...

Scisparc Ltd.’s drug discovery joint venture, Mitocarex Bio, has successfully developed its core algorithm for allowing the generation of reliable...

One way to prevent the effect of a molecule is to use the cell’s own machinery to break it down. This is what the PROTAC technology does, an acronym for proteolysis targeting chimera, or BacPROTAC, when applied to bacteria. A study led by Austrian and German scientists has demonstrated the effectiveness of this technique in eliminating the tuberculosis pathogen Mycobacterium tuberculosis (Mtb). The finding opens the door to the BacPROTAC strategy as an alternative to the development of drugs against this microorganism.

Lantern Pharma Inc. has developed highly accurate artificial intelligence (AI) algorithms to predict...

Initial Therapeutics Inc. has launched with a focus on developing medicines that block difficult-to-drug protein targets with a new mode of action – selective termination of protein synthesis (STOPS).

A pill that delivers electrical stimulation to the vagus nerve from inside the stomach was able to trigger the release of appetite-controlling neurohormones, specifically the “hunger hormone” ghrelin. The work, which was described in the April 26, 2023, issue of Science Robotics, could pave the way for treating “metabolic, [gastrointestinal], and neuropsychiatric disorders noninvasively with minimal off-target effects,” the authors wrote in their paper.